文献速递淋巴瘤白血病

儿童、青少年及年轻成人T细胞淋巴母细胞淋巴瘤

T-cell lymphoblastic lymphoma in children, adolescents and young adults.
PubMed 文献 · Br J Haematol · 2025-08-13

本文综述儿童T细胞淋巴母细胞淋巴瘤(T-LBL)的临床表现、免疫表型与分子特征,指出其与T细胞急性淋巴细胞白血病(T-ALL)虽被WHO归为同一实体但存在临床与分子差异。近期研究显示NOTCH1融合为儿童T-LBL所独有,与复发风险增加相关。综述强调可测量残留病适用性有限、缺乏统一风险分层,需T-LBL特异性治疗策略与协作研究。

要点

  • T-LBL与T-ALL以诊断时骨髓原始细胞≥25%区分,但WHO仍归为同一实体。
  • NOTCH1融合为儿童T-LBL独有、T-ALL中缺失,与复发风险增加相关。
  • 可测量残留病在T-LBL中适用性有限,且缺乏统一的风险分层体系。

核心结论

  • 综述强调亟需基于生物学、风险适应的治疗策略与协作研究,以改善儿童T-LBL患者的治疗与结局。

研究设计与样本

  • 本文为综述,聚焦儿童T-LBL,汇总其临床表现、免疫表型与分子 landscape 的当前认识。

主要发现

  • T-LBL是儿童和青少年中第二常见的非霍奇金淋巴瘤(NHL)亚型。
  • T-LBL与T-ALL共享大量生物学和临床特征,临床上以诊断时骨髓受累程度区分,T-ALL定义为骨髓原始细胞≥25%。
  • 尽管WHO将T-LBL与T-ALL归为单一实体,新出现的数据提示两者存在相关临床与分子差异。
  • 近期研究识别出NOTCH1融合为儿童T-LBL所独有、在T-ALL中缺失,并与复发风险增加相关。
  • 综述指出可测量残留病适用性有限、缺乏统一风险分层,并需T-LBL特异性治疗调整。

关键数值与推荐

  • T-ALL定义为诊断时骨髓原始细胞≥25%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 综述指出可测量残留病的适用性有限。
  • 综述指出缺乏统一的风险分层。
  • 综述指出需要T-LBL特异性的治疗调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-cell lymphoblastic lymphoma (T-LBL) is the second most common subtype of non-Hodgkin lymphoma (NHL) in children and adolescents. T-LBL shares considerable biological and clinical features with T-cell acute lymphoblastic leukaemia (T-ALL). The two entities are clinically distinguished by the extent of bone marrow (BM) involvement at diagnosis, with T-ALL defined by ≥25% blasts in the BM. Although the WHO classifies T-LBL and T-ALL as a single entity, emerging data suggest relevant clinical and molecular differences. This review focuses on T-LBL in paediatric patients, summarizing current knowledge on its clinical presentation, immunophenotype and molecular landscape. We further explore age-associated genomic patterns, recurrent mutations and chromosomal aberrations, with a particular focus on their prognostic relevance. Notably, recent studies have identified NOTCH1-fusions as exclusive to paediatric T-LBL, absent in T-ALL, and are associated with an increased risk of relapse. We highlight the limited applicability of measurable residual disease, lack of harmonized risk stratification and the need for T-LBL-specific treatment adaptations. Ultimately, this review emphasizes the urgent need for biologically informed, risk-adapted treatment strategies and collaborative research efforts to advance care and outcomes of paediatric patients with T-LBL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Te Vrugt M, Newman H, Teachey DT, et al. T-cell lymphoblastic lymphoma in children, adolescents and young adults. Br J Haematol. 2025. PMID: 40808247. doi:10.1111/bjh.70053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。